ITOG Selumetinib Trial Achieves Accrual Goal!
ITOG Selumetinib Trial Achieves Accrual Goal!
Congratulations to Principal Investigator: Alan Ho, MD at Memorial Sloan-Kettering Cancer Center and his team for achieving accrual goal of 60 for the Selumetnib plus RAI for RAI-Avid Thyroid Cancer.
Recent Posts
The International Thyroid Oncology Group (ITOG) is pleased to announce that Dr. Saad Kenderian and Dr. Al [...]
Catch up on the latest from ITOG—research progress, community updates, and highlights shaping the future of thyroid [...]
